Ligufalimab (CD47) Combination Therapy Shows Promise in Frontline AML Treatment
Recent Phase II trial results presented at EHA 2026 indicate that ligufalimab-based combination therapy may significantly improve outcomes for patients with frontline acute myeloid leukemia (AML). The study highlights deep responses and survival benefits, marking a potential breakthrough in AML treatment strategies.